Literature DB >> 8918748

Type II mixed cryoglobulinaemia, hepatitis C virus infection, and glomerulonephritis.

A Fornasieri1, G D'Amico.   

Abstract

Mixed cryoglobulins (MC) are immunoglobulins which precipitate reversibly in the cold. Type II mixed cryoglobulins are composed of a monoclonal component (usually IgMk) with rheumatoid factor (RF) activity against polyclonal IgG. In type III MC, all the components are polyclonal. The majority of MC are secondary to connective tissue diseases, infectious or lymphoproliferative disorders, hepatobiliary diseases, or immunologically mediated glomerular diseases. The aetiology of MC is not clear and cryoglobulinaemia was considered 'essential' until an association between hepatitis C virus (HCV) infection and MC was recognized. The renal pattern includes typical glomerular lesions characterized by a particular glomerular monocyte infiltration, double-contoured appearance of the glomerular basement membrane (GBM) and by the presence of intraluminal 'hyaline thrombi' due to deposition of circulating cryoglobulins. The progression of renal disease is variable: in one-third of patients remission of renal symptoms occurs, 20% of patients experienced nephritic or nephrotic flare-ups during the course of the disease. Uraemia is observed in only 10% of patients 10 years after renal disease onset, but 50% of patients had already died from cardiovascular disease, infectious liver failure, or neoplasia during those 10 years. This review analyses the pathogenic mechanisms of MC and associated GN, with particular attention to the role of HCV infection. HCV RNA is detected in most patients with MC. HCV, by infecting B cells, could trigger abnormal production of polyclonal RF in type III MC and, together with other factors, a clone selection of B cells to produce monoclonal IgMk RF in type II MC. The presence of IgMk in serum appears essential for glomerular damage to occur. Cryoglobulinaemic GN might be initiated by IgG antibody-HCV complexes binding to IgMk RF, either in situ or in circulation, nephrotoxicity being due to a particular affinity of the IgMk RF for cellular fibronectin present in the mesangial matrix. Glomerular damage can be perpetuated by the reduced effectiveness of monocytes to remove cryoglobulins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8918748     DOI: 10.1093/ndt/11.supp4.25

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

1.  Pancreatic involvement in chronic viral hepatitis.

Authors:  Yoshiki Katakura; Hiroshi Yotsuyanagi; Kiyoe Hashizume; Chiaki Okuse; Noriaki Okuse; Kohji Nishikawa; Michihiro Suzuki; Shiro Iino; Fumio Itoh
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

2.  Effect of circulating immune complexes on the binding of rheumatoid factor to histones.

Authors:  H A Gussin; K L Russo; M Teodorescu
Journal:  Ann Rheum Dis       Date:  2000-05       Impact factor: 19.103

Review 3.  Cryoglobulinaemic vasculitis: classification and clinical and therapeutic aspects.

Authors:  Gerald S Braun; Sophia Horster; Katrin S Wagner; Stephan Ihrler; Holger Schmid
Journal:  Postgrad Med J       Date:  2007-02       Impact factor: 2.401

Review 4.  Hepatitis C virus-associated extrahepatic manifestations: a review.

Authors:  Damien Sène; Nicolas Limal; Patrice Cacoub
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 5.  Vasculitis: determinants of disease patterns.

Authors:  Gary S Hoffman; Leonard H Calabrese
Journal:  Nat Rev Rheumatol       Date:  2014-06-17       Impact factor: 20.543

Review 6.  Hepatitis C virus infection induced vasculitis.

Authors:  Patrice Cacoub; David Saadoun
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

7.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  Infection       Date:  2018-09-25       Impact factor: 3.553

8.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  J Nephrol       Date:  2018-09-25       Impact factor: 3.902

9.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  Intern Emerg Med       Date:  2018-09-25       Impact factor: 3.397

Review 10.  Hepatitis C virus associated glomerulopathies.

Authors:  Abdullah Ozkok; Alaattin Yildiz
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.